Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- BASEL-PMI: Does Cardiologist Evaluation in Patients With PMI Reduce CV Risk?One year after major noncardiac surgery, patients who received an evaluation for perioperative myocardial infarction/injury (PMI) by a cardiologist had a lower risk of all-cause mortality and major cardiac events, according to a multicenter prospective study published Jan. 30 in EHJ. The findings suggest that interdisciplinary management may improve postoperative outcomes in patients with PMI.
- COACT 5 Year Data: Similar Survival With Immediate vs. Delayed Coronary Angiography in OHCA SurvivorsAt five years, survival was comparable between immediate and delayed angiography with no clinical benefit or harm in patients without ST-segment elevation resuscitated from out-of-hospital cardiac arrest (OHCA), according to new results from the randomized COACT trial published Feb. 4 in JACC.
- Substantial Hospital-Level Variation in Immediate Coronary Angiography Among Patients With STEMI and OHCA | NCDR StudyAmong patients presenting with both out-of-hospital cardiac arrest (OHCA) and STEMI, substantial hospital-level variation was found in providing immediate coronary angiography (CA), according to a Brief Report published Feb. 11 in JACC.
- ACCEL Lite: VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or StrokeIn this interview, Nanette Kass Wenger MD, MACC and Erin A. Bohula, MD, FACC discuss the VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke.
- CORALreef Lipids: Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in High-Risk PatientsEnlicitide decanoate, an oral PCSK9 inhibitor, significantly reduced LDL-C levels in patients with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event, according to results of the CORALreef Lipids trial published Feb. 4 in the NEJM.



